These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16168810)

  • 1. Changes in cardiac tissue characterization in carriers with gene mutations associated with hypertrophic cardiomyopathy.
    Kaneda T; Shimizu M; Ino H; Yamaguchi M; Terai H; Fujino N; Nagata M; Sakata K; Mabuchi H
    Int J Cardiol; 2005 Sep; 104(2):170-5. PubMed ID: 16168810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.
    Hiremath P; Lawler PR; Ho JE; Correia AW; Abbasi SA; Kwong RY; Jerosch-Herold M; Ho CY; Cheng S
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.
    Konno T; Shimizu M; Ino H; Fujino N; Uchiyama K; Mabuchi T; Sakata K; Kaneda T; Fujita T; Masuta E; Mabuchi H
    Clin Sci (Lond); 2006 Jan; 110(1):125-31. PubMed ID: 16181148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial ultrasound tissue characterization in patients with hypertrophic cardiomyopathy: noninvasive evidence of electrical and textural substrate for ventricular arrhythmias.
    Limongelli G; Pacileo G; Cerrato F; Verrengia M; Di Simone A; Severino S; Sarubbi B; Calabrò R
    J Am Soc Echocardiogr; 2003 Aug; 16(8):803-7. PubMed ID: 12878988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
    Revera M; van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
    Cardiovasc Res; 2008 Mar; 77(4):687-94. PubMed ID: 18029407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic differences between electrocardiographic and echocardiographic determination of hypertrophic cardiomyopathy in genetically affected subjects.
    Konno T; Shimizu M; Ino H; Fujino N; Hayashi K; Uchiyama K; Kaneda T; Inoue M; Masuda E; Mabuchi H
    J Intern Med; 2005 Sep; 258(3):216-24. PubMed ID: 16115294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy.
    Abchee A; Marian AJ
    J Investig Med; 1997 Apr; 45(4):191-6. PubMed ID: 9154300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.
    Canciello G; Lombardi R; Borrelli F; Ordine L; Chen SN; Santoro C; Frisso G; di Napoli S; Polizzi R; Cristiano S; Esposito G; Losi MA
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?
    Santambrogio GM; Maloberti A; Vallerio P; Peritore A; Spanò F; Occhi L; Musca F; Belli O; De Chiara B; Casadei F; Facchetti R; Turazza F; Manfredini E; Giannattasio C; Moreo A
    Int J Cardiovasc Imaging; 2019 Dec; 35(12):2167-2175. PubMed ID: 31321652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Long Term Follow-up Study of Carriers of Hypertrophic Cardiomyopathy Mutations.
    McTaggart DR; Ogden KJ; Marathe JA
    Heart Lung Circ; 2017 Jan; 26(1):18-24. PubMed ID: 27373729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial ultrasonic tissue characterization for estimating histological abnormalities in hypertrophic cardiomyopathy: comparison with endomyocardial biopsy findings.
    Mizuno R; Fujimoto S; Yamaji K; Yutani C; Hashimoto T; Nakamura S
    Cardiology; 2001; 96(1):16-23. PubMed ID: 11701936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene mutations in apical hypertrophic cardiomyopathy.
    Arad M; Penas-Lado M; Monserrat L; Maron BJ; Sherrid M; Ho CY; Barr S; Karim A; Olson TM; Kamisago M; Seidman JG; Seidman CE
    Circulation; 2005 Nov; 112(18):2805-11. PubMed ID: 16267253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-layer ultrasonic tissue characterization of the ventricular septum is predictive of prognosis in patients with non-obstructive hypertrophic cardiomyopathy.
    Kawasaki T; Yamano M; Kuribayashi T; Kaimoto S; Miki S; Kamitani T; Matsubara H; Sugihara H
    Eur J Echocardiogr; 2011 Feb; 12(2):90-7. PubMed ID: 20810448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.
    Crilley JG; Boehm EA; Blair E; Rajagopalan B; Blamire AM; Styles P; McKenna WJ; Ostman-Smith I; Clarke K; Watkins H
    J Am Coll Cardiol; 2003 May; 41(10):1776-82. PubMed ID: 12767664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
    Ho CY; López B; Coelho-Filho OR; Lakdawala NK; Cirino AL; Jarolim P; Kwong R; González A; Colan SD; Seidman JG; Díez J; Seidman CE
    N Engl J Med; 2010 Aug; 363(6):552-63. PubMed ID: 20818890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression.
    Revera M; Van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
    Cardiovasc J Afr; 2007; 18(3):146-53. PubMed ID: 17612745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of transmural trend of myocardial integrated ultrasound backscatter for differentiation of hypertrophic cardiomyopathy and ventricular hypertrophy due to hypertension.
    Naito J; Masuyama T; Tanouchi J; Mano T; Kondo H; Yamamoto K; Nagano R; Hori M; Inoue M; Kamada T
    J Am Coll Cardiol; 1994 Aug; 24(2):517-24. PubMed ID: 8034891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and ECG variables to predict the outcome of genetic testing in hypertrophic cardiomyopathy.
    Robyns T; Breckpot J; Nuyens D; Vandenberk B; Corveleyn A; Kuiperi C; Van Aelst L; Van Cleemput J; Willems R
    Eur J Med Genet; 2020 Mar; 63(3):103754. PubMed ID: 31513939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.
    Germans T; Wilde AA; Dijkmans PA; Chai W; Kamp O; Pinto YM; van Rossum AC
    J Am Coll Cardiol; 2006 Dec; 48(12):2518-23. PubMed ID: 17174192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.